Clinical Trial

Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans

Study acronym: APP
Recruiting
View on ClinicalTrials.gov →
Summary
The two pancreatic hormones amylin and pancreatic polypeptide (PP) has been linked to satiety and energy metabolism. The goal of this this study is to determine the separate and combined effects of the two hormones on food intake and other exploratory endpoints related to metabolism in healthy humans. The aim of this study is to investigate the interaction between the hormones and obtain insight into the physiology of the hormones. The healthy participants will undergo 4 study days in a randomised order receiving the following infusions for 5 hours: A) Amylin + PP B) Amylin + Placebo C) Placebo + PP D) Placebo + Placebo Throughout the day blood samples will be collected and gallbladder motility will be evaluated. Further, indirect calorimetry and heart rate/blood pressure measurement will be performed.
Trial Details
NCT Number NCT07506369
Lead Sponsor University Hospital, Gentofte, Copenhagen
Conditions Obesity & Overweight
Enrollment 18 participants
Start Date 2026-04
Primary Completion 2026-10 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-01